Atheromatous embolization.
Atheromatous embolization is a multisystem disease complicating advanced atherosclerosis. It occurs most often as a complication of angiography, an endovascular procedure or cardiovascular surgery. Atheromatous embolization can present in a subtle manner where it is often under-recognized, or with catastrophic results including myocardial infarction, strake or acute renal failure. It may mimic other disease processes and often goes underdiagnosed and undertreated. A high clinical suspicion is the key to diagnosis. Atheromatous embolization results in significant morbidity and mortality; therefore, early recognition followed by aggressive management may help to prevent end-organ damage and improve overall clinical outcomes. Management strategies should include risk factor modification, prevention of further insults by discontinuing or avoiding predisposing factors, supportive treatment and interventional or surgical approaches to remove the atheroembolic source. Atheromatous embolization is expected to increase as our population ages and the epidemics of diabetes mellitus and obesity increase.
Liew
Yin Ping
YP
Department of Cardiovascular Medicine, Section of Vascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Bartholomew
John R
JR
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000792:Angiography; D050197:Atherosclerosis / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D006348:Cardiac Surgical Procedures; D003937:Diagnosis, Differential; D017700:Embolism, Cholesterol / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007674:Kidney Diseases / Q000175:diagnosis / Q000628:therapy; D012307:Risk Factors; D017445:Skin Diseases, Vascular / Q000175:diagnosis / Q000628:therapy
D000305:Adrenal Cortex Hormones; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors